2015•MD Conference ExpressRequires access

Targeted and Salvage Therapies Benefit Patients With Thyroid Cancer

K. Boltz, Maya Shah, Ezra E.W. Cohen, Maria E. Cabanillas

Abstract

Sorafenib and lenvatinib can be effective for advanced differentiated thyroid cancer, and vandetanib and cabozantinib can be effective options for advanced medullary thyroid cancer. When first-line tyrosine kinase inhibitors fail for patients, evidence supports salvage therapy for differentiated thyroid cancer but is less compelling for medullary thyroid cancer.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Lenvatinib, Cabozantinib, Vandetanib, Sorafenib, Medullary thyroid cancer, Thyroid cancer, Medicine, Oncology